August Biomedical Corp. Expands Senior Management; Appoints Mr. Paul Witzel as Chief Financial Officer


LAS VEGAS, April 30, 2003 (PRIMEZONE) -- August Biomedical Corp. (OTCBB:AGBM) ("August") today announced the appointment of Mr. Paul Witzel as Chief Financial Officer, who will assume a seat on the board of directors effective May 1, 2003.

The announcement was made by Mr. Peter Whitehead, Director, who also announced that Ms. Korina Houghton, current Chief Financial Officer, will resign from the company and its board of directors.

Mr. Witzel has been President of The Paul Witzel Corporation, a private consulting company providing services to public and private companies, and President of Witzel Capital Corp., a private investment company providing funding to ventures.

Since 1996, Mr. Witzel has been semi-retired focusing on private land and stock investments; acting as a business consultant to Mission North America (an International Christian non-profit); serving as Chief Financial Officer and director for Lattice Capital Corp., a capital pool corporation listed on the TSX Venture Exchange; a director of Global Light Telecommunications Ltd. (formerly AMEX and TSX listed); and pursuing other non-business interests.

Previously, Mr. Witzel has been an officer and director of many public companies. Accomplishments have included successfully raising over $100 million in financings, leading companies as President and successfully negotiating joint ventures with major public companies. Mr. Witzel has successfully run in partnership his own public accounting practice and assisted an international accounting firm setting up their private business division.

Mr. Witzel is a Chartered Accountant and holds a degree in mathematics.

AUGUST Biomedical Corp. (www.augustbio.com) is a medical technology company that develops, manufactures and markets next-generation proprietary dental and surgical imaging systems and devices aiding in the detection and localization of oral and cervical cancer.

This document may contain certain forward-looking statements regarding August Biomedical Corp., including statements about its operations, prospects and expectations about future financial results, including, but not limited to, future revenues and earnings. The words "estimate," "possible," "expects," "anticipates," believes," "seeking," and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. These forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially and are subject to change at any time. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including those risks and uncertainties detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2001 filed with the SEC as well as subsequent forms B-Ks, 10-Qs, 14-C and S-8 registrations.


            

Coordonnées